Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
You may also be interested in...
People In Brief
Ex-Baxter CEO: Harry Kraemer, who resigned from Baxter in early 2004 following a string of earnings disappointments, joins private equity firm Madison Dearborn Partners as an executive partner April 27 (1"The Gray Sheet" Feb. 2, 2004, p. 11). Currently an adjunct professor at Northwestern University's Kellogg School of Management, Kraemer plans to continue teaching two days a week. Madison Dearborn invests in a wide range of healthcare companies, including kidney dialysis center chain Dialysis Centers of America and ancillary services provider Path Lab Holdings...
People In Brief
Ex-Baxter CEO: Harry Kraemer, who resigned from Baxter in early 2004 following a string of earnings disappointments, joins private equity firm Madison Dearborn Partners as an executive partner April 27 (1"The Gray Sheet" Feb. 2, 2004, p. 11). Currently an adjunct professor at Northwestern University's Kellogg School of Management, Kraemer plans to continue teaching two days a week. Madison Dearborn invests in a wide range of healthcare companies, including kidney dialysis center chain Dialysis Centers of America and ancillary services provider Path Lab Holdings...
Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits
Veridex is rolling out Immunicon's circulating tumor cell selection and enumeration IVD systems to roughly 20 U.S. comprehensive cancer centers and clinical labs